Pay as little as $0 for CIMERLI® co-pay, up to $15,000 per calendar year, for eligible patients with commercial insurance*
Pay as little as $0 for injection co-pay for CIMERLI®, up to $1,000 per calendar year, for eligible patients with commercial insurance*
Commercially insured includes commercial, private, employer, and state-run health insurance exchanges. Coverage and reimbursement for patients with commercial insurance will vary based on health plan benefit design and provider contract.
Cimerli Solutions™ Co-Pay Savings Program
The Cimerli Solutions™ Co-Pay Savings Program is part of the Coherus Solutions™ family of patient support services. Cimerli Solutions™ offers a Co-Pay Savings Program that may cover out-of-pocket expenses related to CIMERLI™ for commercially insured patients.
Eligible patients may qualify for $0 out-of-pocket costs for each CIMERLI® dose, as well as a portion of administration fees associated with the injection of CIMERLI™ for eligible patients with commercial insurance*
If at any time a patient starts receiving coverage through a federal, state, or government-funded healthcare program, the patient will no longer be eligible for either the drug of injection administration programs. The patient MUST contact Coherus Solutions™ at 1-844-483-3692 to report the change in eligibility status.
Restrictions may apply and may not be valid where prohibited by law. Coherus may revise or terminate this program without notice at any time.
There are three ways for a provider to receive reimbursement for CIMERLI® (ranibizumab-eqrn) injection from the Co-Pay Savings Program:
Payment Remittance: If you have an account with InstaMed® and have elected to receive payments via ACH and electronic remittance, then approved claims will be paid via ACH. If you do not have an account with InstaMed® or did not elect to receive ACH payments, then a physical check for approved claims will be mailed to the address on the claim form submitted for reimbursement.
There are 3 ways to set up an account to receive payments via ACH and electronic remittance:
a. Online: https://online.instamed.com/providers
b. Email: support@InstaMed.com
c. Call: InstaMed® Support at 1-866-467-8263
Please contact InstaMed® customer service directly at 1-866-467-8263 if you are unaware of your current InstaMed® account status.
Select a payment type for addistional details:
|Payment Method||Steps Required|
|Check will be mailed to the address listed on the CMS‑1500 or CMS‑1450 claim form. Reimbursement to a specific site when provider has multiple locations.|
If your practice has already elected to receive payments via ACH and electronic remittance for other payers, then approved claims will be paid via EFT.
If you have not elected to receive payments electronically for other payers, please contact Coherus Solutions™ at 1-844-483-3692 for additional information.
Virtual Debit Card
Once the claim is approved, you will receive a Virtual Debit Card (VDC) Confirmation Fax. This fax will include:
Please use this information to process payment as you would any credit card or debit card payment.
Submit claims through SmartData Solutions (SDS) website:
For assistance with CIMERLI® co-pay claims reimbursement, please contact
Coherus Solutions™ at 1-844-483-3692
Participating patients, pharmacies, physician offices and hospitals may use Coherus’ patient services web portal or send completed enrollment forms to 1-877-226-6370 to enroll patients. Under the program, if a patient incurs a co-pay obligation for the administration of CIMERLI, and meets all eligibility requirements, Coherus shall subsidize the cost of administration up-to $1000 per calendar year. The program benefit will reset every January 1st. Re-enrollment in the program is required at regular intervals. Patients may participate in the program as long as patient re-enrolls as required by Coherus BioSciences and continues to meet all of the program’s eligibility requirements during participation in the program.. After reaching the maximum program benefit, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the program’s benefits cannot exceed the patient’s out-of-pocket expenses for the cost of the drug or administration fees associated with CIMERLI.